Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK
NCT01960374
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
117
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy Volunteers Pharmacokinetic Study
Interventions
DRUG:
Selumetinib
Sponsor
AstraZeneca